loader2
Partner With Us NRI

Krsnaa Diagnostics Ltd share Price Today

Company details

608.00
626.00
435.05
767.90
6M Return -8.40%
1Y Return 37.86%
Mkt Cap.(Cr) 1,984.54
Volume 64,103
Div Yield 0.44%
OI
-
OI Chg %
-
Volume 64,103

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Services company Krsnaa Diagnostics announced Q3FY24 & 9MFY24 results:

Q3FY24 Financial Highlights:

  • In Q3FY24, the core business generated a revenue of Rs 1,583 million, marking a significant 34% year-on-year growth from Rs 1,180 million in Q3FY23.
  • Revenue from operations for the core business in Q3FY24 stood at Rs 1,583 million, compared to Rs 1,181 million in Q3FY23.
  • Other income in Q3FY24 was Rs 41 million, slightly lower than the Rs 45 million reported in Q3FY23.
  • Total income in Q3FY24 reached Rs 1,624 million, compared to Rs 1,226 million in Q3FY23.
  • EBITDA for the core business in Q3FY24 was Rs 378 million, showing a substantial 27% increase from Rs 298 million in Q3FY23.
  • The EBITDA margin for the core business was 24% in Q3FY24, slightly lower than the 25% reported in Q3FY23.
  • EBIT for the core business in Q3FY24 amounted to Rs 202 million, similar to the Rs 200 million reported in Q3FY23.
  • The EBIT margin for the core business was 13% in Q3FY24, lower than the 17% reported in Q3FY23.
  • Profit after tax (PAT) for the core business in Q3FY24 was Rs 130 million, representing a 5% decrease from Rs 136 million in Q3FY23.
  • The PAT margin for the core business was 8% in Q3FY24, lower than the 12% reported in Q3FY23.
  • The reported diluted earnings per share (EPS) for the core business in Q3FY24 was Rs 3.97, compared to Rs 4.24 in Q3FY23.

9MFY24 Financial Highlights:

  • Core business revenue amounted to Rs 4,533 million, reflecting a robust 28% year-on-year growth from Rs 3,532 million in 9MFY23.
  • Revenue from operations totaled Rs 4,533 million, up from Rs 3,539 million in 9MFY23.
  • Other income amounted to Rs 125 million, down from Rs 135 million in 9MFY23.
  • Total income was Rs 4,658 million, up from Rs 3,674 million in 9MFY23.
  • EBITDA stood at Rs 1,020 million, compared to Rs 891 million in 9MFY23.
  • EBITDA margin was 23%, consistent with the margin in 9MFY23.
  • EBIT totaled Rs 566 million, down from Rs 621 million in 9MFY23.
  • EBIT margin was 12%, consistent with the margin in 9MFY23.
  • PAT amounted to Rs 381 million, down from Rs 432 million in 9MFY23.
  • PAT margin was 8%, down from 12% in 9MFY23.
  • Over the nine months of FY24, the reported diluted EPS was Rs 11.71, down from Rs 13.42 in 9MFY23.

Operational Highlights for Q3FY24:

  • Krsnaa has been short-listed to provide 17 MRI and 17 CT scan services in Maharashtra.
  • Krsnaa has been shortlisted to provide MRI services in 5 Districts in Madhya Pradesh.
  • Bagged contract to provide HPLC test at 21 districts in Maharashtra.
  • Krsnaa has operationalized the pathology project in Assam.
  • Krsnaa expanded its presence by establishing 195 new centers across the nation.

Commenting on the Business, Pallavi Bhatevara, Managing Director, said: "We are one of the leaders benefiting from the transformation in the diagnostic industry, with the government's focus on providing the best healthcare facilities to all. In the Interim budget, there has been a focus on increasing the number of medical colleges pan India and including ASHA workers and Anganwadi Workers and helpers in the Ayushman Bharat Scheme. These policy measures would bring more people under the fold of public healthcare.

Krsnaa Diagnostics Limited continues to play a major role in providing high-quality and affordable diagnostic services. The provision of high-quality and affordable diagnostic services stands as a fundamental pillar within the healthcare industry.

It is with great pleasure that I announce our successful execution of an agreement for the Assam Pathology tender, a significant opportunity that encompasses 10 Labs and 1,256 collection centers. This development significantly enhances our presence, covering all districts of Assam.

At present, Krsnaa Diagnostics is well-positioned to deploy 54 CT Scan machines, and 24 MRI machines, establish 156 labs, and set up 2,768 collection centers, all under various contractual agreements. These recent contract wins underscore the exceptional capabilities of our in-house teams, reflecting their proficiency in navigating the intricate bidding process, meeting all requirements, and ultimately securing these contracts. As we embark on these projects, Krsnaa Diagnostics is actively expanding its footprint into new geographical regions, establishing a solid foundation for sustainable, long-term growth."

Result PDF

View Other Company Results

Krsnaa Diagnostics Ltd shares SWOT Analysis

Strengths (4)

  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Company with Low Debt
  • Increasing Revenue every Quarter for the past 4 Quarters

Weakness (4)

  • Negative profit growth, promoters decreasing shareholding QoQ
  • MFs decreased their shareholding last quarter
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (0)

Data not found

Threats (2)

  • Promoter decreasing their shareholding
  • Red Flag: Resignation of Top Management

Resistance and support

R1 624.4
R2 634.2
R3 642.4
Pivot

616.20

S1 606.4
S2 598.2
S3 588.4
EMA SMA
621.2
648.3
655.8
633.5
616.5
662.6
671.8
637.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
EAST LANE CAPITAL LLP Block Purchase 2023-10-03 675 150000 NSE
MEDIMAZE SOLUTIONS PRIVATE LIMITED Block Sell 2023-10-03 675 150000 NSE
MIV INVESTMENT SERVICES PRIVATE LIMITED Bulk Purchase 2023-09-28 675 159909 NSE
Name Category Shares
RAJENDRA KHIVRAJ MUTHA PROMOTER 24.87%
KRSNA DIAGNOSTICS (MUMBAI) PRIVATE LIMITED PROMOTER 2.16%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Krsnaa Diagnostics Ltd Stocks COMPARISON

Financials( in Cr) Krsnaa Diagnostics Ltd Apollo Hospitals Enterprise Ltd Max Healthcare Institute Ltd Global Health Ltd Fortis Healthcare Ltd
Price 614.60 6,356.80 819.90 1,321.15 420.20
% Change 1.09 2.01 2.19 -1.42 1.69
Mcap Cr 1,984.54 91,401.25 79,680.01 35,463.23 31,723.34
Revenue TTM Cr 487.12 16,612.50 4,831.37 2,694.25 6,537.06
Net Profit TTM Cr 62.11 887.50 1,103.51 326.08 632.98
PE TTM 34.29 113.67 73.87 79.59 58.24
1 Year Return 37.86 47.21 78.47 179.11 64.69
ROCE 11.26 14.16 13.85 16.49 7.51
ROE 8.73 15.04 16.12 16.13 6.79
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 738.74 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 30,755.54 35,765.55
LAST 3M 69,913.40 30,558.15
LAST 6M 130,081.93 64,349.19
LAST 12M 189,259.39 209,046.49
Krsnaa Diagnostics Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Mar 28, 2024 l NSE Announcement

Krsnaa Diagnostics Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Mar 22, 2024 l NSE Announcement

Date Action Type Ratio
Sep 15, 2023 Dividend 55
Sep 15, 2022 Dividend 50

Krsnaa Diagnostics Ltd Information

Stock PE (TTM)
34.29
Promoter Holding
27.03%
Book Value
234.0357
ROCE
11.26%
ROE
8.73%
Description
  • Krsnaa Diagnostics Limited was originally incorporated as `Krsna Diagnostics Private Limited` at Pune, Maharashtra as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated 22 December 2010. The name of the Company was subsequently changed to `Krsnaa Diagnostics Private Limited`, pursuant to a fresh certificate of incorporation issued by the RoC on 29 January 2015. Thereafter, the Company was converted into a public limited company pursuant to a special resolution passed in the extraordinary general meeting of the Shareholders of our Company held on 25 April 2021 and consequently the name of the Company was changed to its present name pursuant to a fresh certificate of incorporation issued by the RoC on 06 May 2021. The company is primarily engaged in providing diagnostic services centres all over India.The company is providing Radiology and Pathology services for X-ray,CT scan,MRI,Mammography,Tele-Reporting services,all type of blood and urine investigation and other related diagnostic services. The company owns an extensive network of integrated diagnostics centres across India primarily in non-metro and lower-tier cities and towns,with operating 1823 diagnostics centres offering radiology and pathology services in 13 states across the country.The company focuses on the public-private partnership(PPP) diagnostics segment and has the largest presence in the diagnostic PPP segment. During the FY2019, the Company has issued 1000 equity shares of face value of Rs. 10/- each at an offer price of Rs. 328.9597 (including Security Premium of Rs. 318.9597/-). The company also issued 30,38,886 Compulsory Convertible Participating Preference Shares [CCPS] of face value of Rs. 250 each at an offer price of Rs. 328.9597 (including Security Premium of Rs. 78.9597). During the FY2021,the company has allotted 730904 equity shares of Rs 10 each through rights issue. Also the company undertook the conversion of 600960 CCPS -Series B into equity shares in the ratio of 1:1 at a price of Rs 250 per share(including the premium of Rs 240 per share). The company,pursuant to a shareholders` resolution dated 25 April 2021,sub-divided the face value of equity shares from Rs 10 to Rs 5 per share. During the month of August 2021,the company came out with Rs 1213.33 crore IPO which comprised a fresh issue of Rs 400 crore and an offer for sale of Rs 813.33 crore by selling shareholders,including PHI Capital Trust,Kitara and Somerset Indus Healthcare Fund.The company will utilise the fresh issue proceeds for establishing diagnostics centres in Punjab,Karnataka,Himachal Pradesh and Maharashtra and also repaying of debts.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India(NSE) on 16 August 2021.

Registered Address

S.No. 243/A Hissa No.6 Near, Chinchwad Station Chinchwad, Pune, Maharashtra, 411019

Tel : 91-20-46954695
Email : cs:krsnadiagnostics.com
Website : http://www.krsnaadiagnostics.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 543328
NSE Code : KRSNAA
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE08LI01020

FAQ’s on Krsnaa Diagnostics Ltd Shares

You can buy Krsnaa Diagnostics Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Krsnaa Diagnostics Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:55 PM the closing price of Krsnaa Diagnostics Ltd was ₹ 614.60.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:55 PM, the market cap of Krsnaa Diagnostics Ltd stood at ₹ 1,984.54.

The latest PE ratio of Krsnaa Diagnostics Ltd as of Mar 28, 2024 03:55 PM is 34.29

The latest PB ratio of Krsnaa Diagnostics Ltd as of Mar 28, 2024 03:55 PM is 0.38

The 52-week high of Krsnaa Diagnostics Ltd share price is ₹ 767.90 while the 52-week low is ₹ 435.05

Download Our

Download App
market app